The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Starpharma Signs Collaboration and License Agreement with Genentech for Cancer Therapies
Sep 22, 2025•9 months ago
Contract Type
agreement
MelbourneBiotechnologyPharmaceuticalresearch
Description
Starpharma has announced a collaboration and license agreement with Genentech to develop potential cancer treatments using Starpharma’s DEP® technology. The agreement includes an upfront payment of $5.5 million and potential milestones worth up to $564 million.
Company Information
Company
Starpharma
Location
4 Southampton Cres
Melbourne, Victoria, Australia
About
Starpharma is an innovative Australian biotechnology company focused on drug delivery technologies. They specialize in developing dendrimer-based therapies, improving the efficacy and safety profiles of various drugs. Their proprietary DEP® platform offers significant advantages in pharmaceutical development, particularly for cancer therapies.
MelbourneBiotechnologyPharmaceuticalresearch